Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (431-440 of 621) with videos related to

Pageof 63
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic diseaseFrancesco Sclafani, David Gonzalez de Castro, David Cunningham, et al.
JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.
Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
Frontiers in Oncology|December 14, 2023
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patientsHazel Lote, Florentia Mousoullou, George Vlachogiannis, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2023
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden HospitalSu Li, Bhupinder Sharma, Siraj Yusuf, et al.
BMC Cancer|April 14, 2017
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trialsMairéad Geraldine McNamara, John Bridgewater, Andre Lopes, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2014
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumoursTim Meyer, Wendi Qian, Martyn E Caplin, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|June 17, 2025
Characteristics of Ipsilateral Corticomotor Pathways in People with cervical spinal cord InjuryJia Liu, Madeline Cantu, Kyle O'Laughlin, et al.
Lancet (London, England)|April 26, 2013
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesDavid Cunningham, Eliza A Hawkes, Andrew Jack, et al.
Pageof 63

Showing results (431-440 of 621) with videos related to

Sort By:
Pageof 63
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic diseaseFrancesco Sclafani, David Gonzalez de Castro, David Cunningham, et al.
JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.
Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
Frontiers in Oncology|December 14, 2023
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patientsHazel Lote, Florentia Mousoullou, George Vlachogiannis, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2023
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden HospitalSu Li, Bhupinder Sharma, Siraj Yusuf, et al.
BMC Cancer|April 14, 2017
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trialsMairéad Geraldine McNamara, John Bridgewater, Andre Lopes, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2014
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumoursTim Meyer, Wendi Qian, Martyn E Caplin, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|June 17, 2025
Characteristics of Ipsilateral Corticomotor Pathways in People with cervical spinal cord InjuryJia Liu, Madeline Cantu, Kyle O'Laughlin, et al.
Lancet (London, England)|April 26, 2013
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesDavid Cunningham, Eliza A Hawkes, Andrew Jack, et al.
Pageof 63